SLC5A2 and heart failure: Sodium–glucose cotransporter-2 (SGLT2) inhibitors are a class of oral antidiabetic agents that lower blood glucose by promoting urinary glucose excretion and have demonstrated robust benefits in reducing heart failure hospitalization and cardiovascular mortality in type 2 diabetes [71,72,73].